A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations

PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 3, 2015

Primary Completion Date

January 14, 2016

Study Completion Date

January 14, 2016

Conditions
Triple Negative Breast Neoplasms
Interventions
DRUG

PF-03084014

Tablet, 10 mg, twice a day.

DRUG

PF-03084014

Tablet, 50 mg, twice a day

DRUG

PF-03084014

Tablet, 100 mg, twice a day

Trial Locations (37)

4032

Debreceni Egyetem, Klinikai Kozpont, Onkologiai Intezet, Debrecen

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memorial Sloan Kettering Cancer Center Sleepy Hollow, Sleepy Hollow

10604

Memorial Sloan Kettering Cancer Center West Harrison, Harrison

11570

Memorial Sloan Kettering Cancer Center Rockville Centre, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center Commack, Commack

15006

Complejo Hospitalario Universitario A Coruna (Hospital Teresa Herrera), A Coruña

20141

Istitutio Europeo di Oncologia, Milan

28007

Hospital General Universitario Gregorio Maranon, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

31108

Vesalius, Krakow

31216

Vesalius Poradnia Onkologiczna i Hematologiczna, Krakow

41013

Hospital Universitario Virgen del Rocio, Seville

46010

Hospital Clínico Universitario de Valencia, Valencia

60099

Midwestern Regional Medical Center, Zion

60451

University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox

60637

The University of Chicago Medical Center, Chicago

University of Chicago Medical Center, Chicago

73100

Presidio Ospedaliero Vito Fazzi, Lecce

94305

Stanford Cancer Institute, Stanford

Stanford Hospital and Clinics, Stanford

Stanford Women's Cancer Center, Stanford

02115

Brigham and Women's Hospital (BWH), Boston

02215

Dana-Farber Cancer Institute (DFCI), Boston

07920

Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge

07652

The Valley Hospital - Luckow Pavilion, Paramus

Valley Medical Group, Paramus

07675

Valley Medical Group, Westwood

60-569

Szpital Kliniczny Przemienienia Panskiego, Uniwersutetu Medycznego im. Karola Marcinkowskiego, Poznan

08035

Hospital Universitari Vall d'Hebron, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

08908

Instituto Catalan de Oncologia de L'Hospitalet de Llobregat (ICO), Barcelona

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

G52 3NQ

Ross Hall Hospital, Glasgow

SW3 6JJ

The Royal Marsden NHS Foundation Trust, London

SM2 5PT

The Royal Marsden NHS Foundation Trust, Surrey

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02299635 - A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations | Biotech Hunter | Biotech Hunter